Toggle Health Problems and D

Diabetic inflammation reduced by Vitamin D (30,000 IU weekly) – RCT July 2020

Effect of Vitamin D Supplementation on Inflammatory Markers in Non-Obese Lebanese Patients with Type 2 Diabetes: A Randomized Controlled Trial

Nutrients 2020, 12(7), 2033; https://doi.org/10.3390/nu12072033

Better than Daily category listing has 31 items along with related searches

Items in both categories Diabetes and Inflammation are listed here:

Items in both categories Diabetes and Intervention are listed here:

 Download the PDF from VitaminDWiki

by Cynthia El Hajj 1,2,*,Stéphane Walrand 2,Mariana Helou 3 andKaissar Yammine 4

  • 1 Department of Nutrition, Faculty of Natural Sciences, Lebanese American University, Beirut 1102 2801, Lebanon
  • 2 Unité de Nutrition Humaine, France Clermont Université, Université d’Auvergne, INRA, UMR 1019, UNH, CRNH Auvergne, 63009 Clermont-Ferrand, France
  • 3 Department of Medicine, School of Medicine, Lebanese American University, Beirut 1102, Lebanon
  • 4 Department of Orthopedic Surgery, Lebanese American University School of Medecine-Rizk Hospital, Beirut, Lebanon-Center for Evidence-Based Anatomy, Sports & Orthopedic Research, Jdeideh 1102, Lebanon

Background: A low serum 25-hydroxyvitamin D (25(OH) D) concentration has been associated with a higher risk of type 2 diabetes mellitus (T2DM), especially in older people. Our aim in this randomized controlled trial was to evaluate the effect of vitamin D treatment on inflammatory markers in non-obese Lebanese patients with T2DM, living in Beirut, Lebanon.

Methods: Non-Obese patients with T2DM (n = 88), deficient/insufficient in vitamin D, were randomly assigned into one of two groups—a treatment group receiving 30,000 IU cholecalciferol/week for a period of six months, and a placebo group. Serum concentrations of TNF-α, high-sensitivity C-reactive protein (hs-CRP), and Interleukin-6 (IL-6) were the primary outcomes. A homeostatic model of insulin resistance (HOMA-IR) was assessed, in addition to serum concentrations of fasting blood glucose (FBG), HbA1C, (25(OH) D), and PTH.

Results: The vitamin D group showed higher blood levels of (25(OH) D) (p < 0.0001), and a significant reduction in hs-CRP and TNF-α concentrations (p < 0.0001) compared to placebo. The decrease perceived in IL-6 concentrations was not significant (p = 0.1). No significant changes were seen in FBG (p = 0.9) and HbA1c levels (p = 0.85).

Conclusion: Six months of vitamin D supplementation led to a decrease in some inflammatory markers in patients with T2DM. Additional studies with a larger sample and a longer period are advised in this regard. This trial was registered at ClinicalTrial.gov; Identifier number: NCT 03782805.

Created by admin. Last Modification: Thursday July 9, 2020 12:37:10 GMT-0000 by admin. (Version 5)